The medication vibegron led to improvements in symptoms of overactive bladder and overall quality of life in men undergoing treatment for benign prostatic hyperplasia, according to findings from a ...

Chinese investigators evaluated 15 years' worth of data from more than 18,000 adult men in the U.S. to better characterize OAB and its risk factors. The overall presence of OAB increased significantly ...

Men with overactive bladder had significant 95% reduced odds of urinary tract cancers compared with a reference group of men with urolithiasis, after adjusting for age. Overactive bladder (OAB) is ...

A study of NHANES 2005-2020 data found that the prevalence of overactive bladder among men in the US increased significantly from 11.7% in 2009-2014 to 14.5% in 2015-2020. Overactive bladder (OAB) ...

I am in relatively good health for an 82-year-old male. For the past six years, I have been having trouble with an overactive bladder. I need to urinate at least every two hours. Often there is a ...

Please provide your email address to receive an email when new articles are posted on . The proportion of men with overactive bladder increased significantly from 2015 to 2020. Results showed ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA) has ...

Certain healthcare conditions often go unspoken, leading to silent struggles that affect the lives of many. Overactive bladder (OAB) and fecal incontinence (FI) are two such conditions, impacting ...

In the United States today, overactive bladder (OAB) may impact as many as 40 percent of women and 30 percent of men. The chances of developing OAB increase with age but the condition is not a ...

Aggression was more prevalent in men with OAB or LUTS than in men without either condition and contributed to poorer quality of life. The difference in quality of life was statistically significant ...

Credit: Shutterstock. Vibegron is an oral, small molecule beta-3 adrenergic receptor agonist. A phase 3 study evaluating the efficacy and safety of vibegron in men with overactive bladder (OAB) ...